Medicinova Inc Revenue Growth Rates (MNOV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Medicinova Inc   (NASDAQ: MNOV)
 

MNOV's Revenue Growth by Quarter and Year

Medicinova Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MNOV/growth
https://api.csimarket.com/api/v1/companies/MNOV/fundamentals
https://api.csimarket.com/api/v1/companies/MNOV/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
MNOV Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.14
2nd Quarter June 0.46
1st Quarter March 0.19
FY 0.79

MNOVs Annual Revenue
Medicinova Inc 's Revenue in the fiscal year 2025 $ 0.41 millions
Medicinova Inc 's Revenue in the fiscal year 2024 $ 0.00 millions
Medicinova Inc 's Revenue in the fiscal year 2023 $ 1.00 millions
Medicinova Inc 's Revenue in the fiscal year 2022 $ 0.00 millions
Medicinova Inc 's Revenue in the fiscal year 2021 $ 4.04 millions




MNOV Revenue third quarter 2026 Y/Y Growth Comment
Medicinova Inc achieved in the third quarter 2026, above Company average Revenue increase of 15.46% year on year, to $ 0.14 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Revenue growth. While Medicinova Inc ' s Revenue growth of 15.46% ranks overall at the positon no. 317 in the third quarter 2026.


MNOV Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 15.46 %
2nd Quarter June 253.85 %
1st Quarter March -
FY   -

Financial Statements
Medicinova Inc 's third quarter 2026 Revenue $ 0.14 millions MNOV's Income Statement
Medicinova Inc 's third quarter 2025 Revenue $ 0.12 millions Quarterly MNOV's Income Statement


MNOV Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -69.88 %
2nd Quarter June 142.11 %
1st Quarter March 26.67 %
FY (Year on Year)   -


Back to MNOV Growth rate Comparisons >> Back to MNOV Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #46
Healthcare Sector #86
Overall #317

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #46
Healthcare Sector #86
Overall #317
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Medicinova Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
158.21 % -30.12 % -100 %
(Jun 30 2012)  


MNOV's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Medicinova Inc disclosed fall in Revenue from the second quarter by -69.88% to $ 0.14 millions, from $ 0.46 millions achived in the previous reporting period.

But that's not important problem, as Medicinova Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 21 other companies have achieved higher Revenue quarter on quarter growth. While Medicinova Inc 's Revenue growth quarter on quarter, overall rank is 107.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #22
Healthcare Sector #37
Overall #107
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #22
Healthcare Sector #37
Overall #107
Revenue Q/Q Growth Statistics
High Average Low
158.21 % -30.12 % -100 %
(Jun 30 2012)  


MNOV's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Medicinova Inc disclosed fall in Revenue from the second quarter by -69.88% to $ 0.14 millions, from $ 0.46 millions achived in the previous reporting period.

But that's not important problem, as Medicinova Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 21 other companies have achieved higher Revenue quarter on quarter growth. While Medicinova Inc 's Revenue growth quarter on quarter, overall rank is 107.


Medicinova Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 0.94
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) 1.66 %
Seq. Revenue Growth (TTM) Overall Ranking # 320


Cumulative Revenue growth Comment
Medicinova Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 15.46% year on year, to $ 1 millions if the fiscal year would have ended in Sep 30 2026.
Medicinova Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2026. And, Medicinova Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Jun 30 2026 rise was beneth at 1.66 % from $0.92 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.

Medicinova Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 46
Sector # 86
S&P 500 # 320
Cumulative Revenue growth Comment
Medicinova Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 15.46% year on year, to $ 1 millions if the fiscal year would have ended in Sep 30 2026.
Medicinova Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2026. And, Medicinova Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Jun 30 2026 rise was beneth at 1.66 % from $0.92 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 1.66 % increase from $0.92 millions in the period from Jun 30 2026 to Sep 30 2025.

Medicinova Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 46
Sector # 86
S&P 500 # 320




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MNOV's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Vericel Corporation26.47%$ 26.470 millions
Axogen inc 26.22%$ 26.218 millions
Cardio Diagnostics Holdings Inc 25.74%$ 25.744 millions
Edap Tms Sa25.55%$ 25.549 millions
Lifestance Health Group Inc 25.30%$ 25.303 millions
Rockwell Medical inc 25.21%$ 25.210 millions
Intelligent Bio Solutions Inc 25.19%$ 25.188 millions
The Oncology Institute Inc 24.31%$ 24.313 millions
Vanda Pharmaceuticals Inc 24.10%$ 24.098 millions
Mannkind Corporation24.04%$ 24.035 millions
Castle Biosciences Inc 23.90%$ 23.901 millions
Coherus Oncology inc 23.36%$ 23.360 millions
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions
Atrium Therapeutics Inc 22.81%$ 22.814 millions
Capsovision Inc 22.44%$ 22.443 millions
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions


About Medicinova Inc Revenue Growth Rates (MNOV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Medicinova Inc (CIK 1226616).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-458562
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Medicinova Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.